New drugs: Liraglutide, dalfampridine, and abobotulinumtoxinA.
Hussar
Daniel A
DA
Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, PA, USA.
Kaczinski
Jessica
J
D015761:4-Aminopyridine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003920:Diabetes Mellitus / Q000188:drug therapy*; D017277:Drug Approval; D052216:Glucagon-Like Peptide 1 / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000069450:Liraglutide; D009103:Multiple Sclerosis / Q000188:drug therapy*; D009465:Neuromuscular Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D026902:Potassium Channel Blockers / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014103:Torticollis / Q000188:drug therapy*; D014481:United States; D014486:United States Food and Drug Administration
D007004:Hypoglycemic Agents; D009465:Neuromuscular Agents; D026902:Potassium Channel Blockers; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1; D015761:4-Aminopyridine; D019274:Botulinum Toxins, Type A; C542869:abobotulinumtoxinA